Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy.

BMJ case reports - 30 Dec 2021

Sakamoto Tomohiro, Arai Katsunori, Makishima Karen, Yamasaki Akira

Abstract excerpt

We present a case of combined large cell neuroendocrine carcinoma (LCNEC), harbouring a BRAF V600E mutation, which significantly benefited from BRAF-targeted therapy. A 57-year-old woman was referred to our hospital for headache and vomiting. A head MRI showed a large tumour in her brain, and a whole-body CT revealed a tumour in the hilum of the right lung and mediastinal lymphadenopathies. Both the resected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 34969785
DOI: 10.1136/bcr-2021-243295
PMCID: PMC8719127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy.PMID 34969785Read ↗

BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.Semantic proximity Read ↗

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.Semantic proximity Read ↗

The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the LungSemantic proximity Read ↗

Biology and novel therapeutics for neuroendocrine tumors of the lung.Semantic proximity Read ↗

In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.Semantic proximity Read ↗

ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literatureSemantic proximity Read ↗

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.Semantic proximity Read ↗

Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal originSemantic proximity Read ↗

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?Semantic proximity Read ↗

New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impactsSemantic proximity Read ↗

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.Semantic proximity Read ↗

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.